Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback